Biotie, UCB deal

Biotie and UCB reached a formal agreement to return to Biotie exclusive, worldwide rights to tozadenant ( SYN115), which is in development for Parkinson's disease. In March, UCB said it would terminate an amended 2010 deal with Biotie granting UCB the rights to tozadenant. The transfer is expected to be completed by year end. UCB will contribute a portion of the short-term development costs related to the termination, which UCB will be able to recover from future revenues generated by Biotie. ...